US equities |
SPCX $168.72 ▲+6.14% NVDA $237.53 ▲+1.53% MU $1,065.29 ▼-0.89% TSLA $380.61 ▲+2.70% MSFT $524.63 ▲+1.37% SNDK $1,714.31 ▼-0.33% INTC $116.83 ▼-2.10% META $744.05 ▲+2.19%
FinancialContent

Innate Pharma S.A. - American Depositary Shares (NQ:IPHA)

1.600 +0.040 (+2.56%)
Delayed Quote Updated: 1:34 PM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Innate Pharma S.A. - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
News headline image
Innate Pharma Highlights Preclinical Antitumor Activity of IPH6501 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma at the 2025 European Hematology Association (EHA) Congress
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma Announces Its Participation in Jefferies and Goldman Sachs Healthcare Conferences
From Innate Pharma SA
Via Business Wire
News headline image
Outcome of Innate Pharma’s 2025 Annual General Meeting
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma Highlights Durable Responses to Lacutamab in Sezary Syndrome and Mycosis Fungoides
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma Highlights Abstracts Selected for ASCO 2025 Annual Meeting
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma Highlights ANKET® Abstracts Selected for the EHA 2025 Congress
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma Reports First Quarter 2025 Business Update and Financial Results
From Innate Pharma SA
Via Business Wire
News headline image
Number of Shares and Voting Rights of Innate Pharma as of May 5, 2025
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma announces conference call and webcast for Q1 2025 business update
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma Files Its 2024 Universal Registration Document (Document d’enregistrement universel) and 2024 Annual Report on Form 20-F
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma Highlights Preclinical Anti-Tumor Efficacy Data of Its Antibody Drug Conjugate IPH4502 at the AACR 2025 Annual Meeting
From Innate Pharma SA
Via Business Wire
News headline image
Number of Shares and Voting Rights of Innate Pharma as of April 25, 2025
From Innate Pharma SA
Via Business Wire
News headline image
French Drugmaker Sanofi Clocks 20% Q1 Profit Growth, Forecasts Strong Rebound In Annual Profit ↗
Sanofi Q1 2025 revenue rose 10.8% to $10.42 billion, driven by Dupixent and new launches, as earnings climbed 20.1% and 2025 guidance was reaffirmed. 
Via Benzinga
News headline image
Innate Pharma Announces €15M Investment by Sanofi
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma Regains Its Rights on CD123 Targeting ANKET® and Announces Sanofi’s Intention to Make a Strategic Investment in the Company
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma Proposes to Its Shareholders to Transform Its Corporate Governance Structure Into a Board of Directors and to Change Its Composition
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 22, 2025
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma to Participate in the 2025 Stifel Virtual Targeted Oncology Forum
From Innate Pharma SA
Via Business Wire
News headline image
Earnings Scheduled For March 27, 2025 ↗
 
Via Benzinga
News headline image
Innate Pharma Reports Full Year 2024 Financial Results and Business Update
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma Highlights Antibody Drug Conjugate IPH4502 Abstract Selected for the AACR 2025 Annual Meeting
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma announces its participation in the Life Sciences Van Lanschot Kempen Conference
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma Announces Conference Call and Webcast for Full Year 2024 Financial Results
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma to Participate in the 2025 Leerink Partners Global Healthcare Conference
From Innate Pharma SA
Via Business Wire
News headline image
Wondering what's happening in today's pre-market session? ↗
The US market session of Tuesday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Innate Pharma Announces U.S. FDA Granted Breakthrough Therapy Designation to Lacutamab for Relapsed or Refractory Sézary Syndrome
From Innate Pharma SA
Via Business Wire
News headline image
Why Logility Supply Chain Solutions Shares Are Trading Higher By Over 23%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
Topics Economy
News headline image
Innate Pharma Announces First Patient Dosed in Phase 1 Study of Its Nectin-4 Targeting Antibody Drug Conjugate IPH4502 in Selected Advanced Solid Tumors
From Innate Pharma SA
Via Business Wire
News headline image
Innate Pharma Announces Nectin-4 Antibody Drug Conjugate Investor and Analyst Event in New York
From Innate Pharma SA
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >